Peroxisome proliferator-activated receptor α (PPARα) mRNA expression in human hepatocellular carcinoma tissue and non-cancerous liver tissue

World Journal of Surgical Oncology

Volumn 9, Issue , 2011, Pages

  Kurokawa, Tsuyoshi ^a   Shimomura, Yoshiharu ^b   Bajotto, Gustavo ^b   Kotake, Katsuhiro ^c   Arikawa, Takashi ^c   Ito, Nobuhiro ^c   Yasuda, Akira ^c   Nagata, Hiroshi ^c   Nonami, Toshiaki ^c   Masuko, Kazuo ^a  

^a Masuko Memorial Hospital and Institute for Medical Research   (Japan)

^b NAGOYA INSTITUTE OF TECHNOLOGY   (Japan)

^c AICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Cpt1a; Cyclin d1; Energy metabolism; carcinogenesis; Hepatocellular carcinoma; Ppar

Indexed keywords

ACYLTRANSFERASE; CARNITINE PALMITOYLTRANSFERASE 1A; CYCLIN D1; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; UNCLASSIFIED DRUG; CCND1 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CANCER CELL; CARCINOGENESIS; CELL METABOLISM; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ANALYSIS; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER RESECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; CASE CONTROL STUDY; COMPARATIVE STUDY; GENETICS; LIVER; LIVER TUMOR; METABOLISM; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION;

CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CYCLIN D1; HUMANS; LIVER; LIVER NEOPLASMS; PPAR ALPHA; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 83455206187     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-9-167     Document Type: Article

References (27)

1. Aoyama T, Peters JM, Iritani N, Nakajima T, Furihata K, Hashimoto T, Gonzalez FJ. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor α (PPARα). J Biol Chem 1998, 273:5678-5684. 10.1074/jbc.273.10.5678, 9488698.
2. Guerre-Millo M, Gervois P, Raspé E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, Staels B. Peroxisome proliferator-activated receptorα activators improve insulin sensitivity and reduce adiposity. J Biol Chem 2000, 275:16638-16642. 10.1074/jbc.275.22.16638, 10828060.
3. Lee CH, Olson P, Evance RM. Minireview: lipid metabolism, metabolic diseases and peroxisome proliferator-activated receptors. Endocrinology 2003, 144:2201-2207. 10.1210/en.2003-0288, 12746275.
4. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A. Activation of human aortic smooth-muscles is inhibited by PPARα but not PPARγ activators. Nature 1998, 393:790-793. 10.1038/31701, 9655393.
5. Jiang C, Ting A, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391:82-86. 10.1038/34184, 9422509.
6. Klaunig JE, Babich MA, Baetcke KP, Cook JC, Corton JC, David RM, DeLuca JG, Lai DY, McKee RH, Peters JM, Roberts RA, Fenner-Crisp PA. PPARalpha agonist-induced rodent tumors: modes of action and human relevance. Crit Rev Toxicol 2003, 33:655-780. 10.1080/713608372, 14727734.
7. Peters JM, Aoyama T, Cattley RC, Usuda N, Hashimoto T, Gonzalez FJ. Role of peroxisome proliferator-activated receptor alpha in altered cell cycle regulation in mouse liver. Carcinogenesis 1998, 19:1989-1994. 10.1093/carcin/19.11.1989, 9855014.
8. Reddy JK, Hashimoto T. Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annu Rev Nutr 2001, 21:193-230. 10.1146/annurev.nutr.21.1.193, 11375435.
9. Reddy JK. Hepatocellular carcinomas in acatalasemic mice treated with nafenopin, a hypolipidemic peroxisome proliferator. Cancer Res 1976, 36:1211-1217.
10. Chomczynski P. A reagent for single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques 1993, 15:532-536.
11. Weber AW. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med 2005, 46:983-995.
12. Kostakoglu L, Goldsmith SJ. PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. J Nucl Med 2004, 45:56-68.
13. Kostakoglu L, Goldsmith SJ. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med 2003, 44:224-239.
14. Delbeke D, Martin WH, Sandler MP, Chapman WC, Wright JK, Pinson CW. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg 1998, 133:510-516. 10.1001/archsurg.133.5.510, 9605913.
15. Takahashi N, Kawada T, Goto T, Yamamoto T, Taimatsu A, Matsui N, Kimura K, Saito M, Hosokawa M, Miyashita K, Fushiki T. Dual action of isoprenols from herbal medicines on both PPAR-gamma and PPAR-alpha in 3T3-L1 adipocytes and HepG2 hepatocytes. FEBS Lett 2002, 514:316-322.
16. Takahashi N, Kawada T, Goto T, Kim CS, Taimatsu A, Egawa K, Yamamoto T, Jisaka M, Nishimura K, Yokota K, Yu R, Fushiki T. Abietic acid activates PPAR-gamma in RAW264.7 macrophages and 3T3-L1 adipocytes to regulate gene expression involved in inflammation and lipid metabolism. FEBS Lett 2003, 550:190-194. 10.1016/S0014-5793(03)00859-7, 12935909.
17. Nakashima H, Nonami T, Shimomura Y, Naruse T. Quantification of mRNAs for pyruvate dehydrogenase kinases in human livers. J Aichi Med Univ Assoc 2001, 29:75-81.
18. Bowker-Kinley MM, Davis WI, Wu P, Harris RA, Popov KM. Evidence for existence of tissue-specific regulation of the mammalian pyruvate dehydrogenase complex. Biochem J 1998, 329:191-196. 1219031, 9405293.
19. Peters JM, Cattley RC, Gonzalez F. Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. Carcinogenesis 1997, 18:2029-2033. 10.1093/carcin/18.11.2029, 9395198.
20. Tsutsumi T, Suzuki T, Shimoike T, Suzuki R, Moriya K, Shintani Y, Fujie H, Matsuura Y, Koike K, Miyamura T. Interaction of hepatitis C virus core protein with retinoid X receptor α modulates its transcriptional activity. Hepatology 2002, 35:937-946. 10.1053/jhep.2002.32470, 11915042.
21. Roy PG, Thompson AM. Cyclin D1 and breast cancer. Breast 2006, 15:718-727. 10.1016/j.breast.2006.02.005, 16675218.
22. Polsy D, Cordon-Cardo C. Oncogene in melanoma. Oncogene 2003, 22:3087-3091. 10.1038/sj.onc.1206449, 12789285.
23. He Y, Franco OE, Jiang M, Williams K, Love HD, Coleman IM, Nelson PS, Hayward SW. Tissue-specific consequences of cyclin D1 overexpression in prostate cancer progression. Cancer Res 2007, 67(17):8188-8197. 10.1158/0008-5472.CAN-07-0418, 17804732.
24. Zhang YJ, Jiang W, Chen CJ, Lee CS, Kahn SM, Santella RM, Weinstein IB. Amplication and over expression of cyclin D1 in human hepatocellular carcinoama. Biochem Biophys Res Commun 1993, 196(2):1010-016. 10.1006/bbrc.1993.2350, 8240318.
25. Choi MJ, Jung KH, Kim D, Lee H, Zheng HM, Park BH, Hong SW, Kim MH, Hong S, Hong SS. Anti-cancer effects of a novel compound HS-113 on cell growth, apoptosis, and angiogenesis in human hepatocellular carcinoma cells. Cancer Lett 2011, 306:190-196. 10.1016/j.canlet.2011.03.005, 21463918.
26. Yokomizo C, Yamaguchi K, Ito Y, Nishimura T, Umemura A, Minami M, Yasui K, Mitsuyoshi H, Fujii H, Tochiki N, Nakajima T, Okanoue T, Yoshikawa T. High expression of p300 in HCC predicts shortened overall survival in association with enhanced epithelial mesenchymal transition of HCC cells. Cancer Lett 2011, 310:140-147. 10.1016/j.canlet.2011.06.030, 21764211.
27. Chevalier S, Roberts RA. Pertubation of rodent hepatocyte growth control by nongenotoxic hepatocarcinogens: mechanisms and lack of relevance for human health (review). Oncol Rep 1998, 5:1319-1327.